RxDoctor Payments Data

Stanley Ardoin, MD

Psychiatry · Norman, OKNPI 1649366998

Payments from drug & device makers

$1,358in general payments, 2019–2025

Across 84 payments — averaging $16.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$531
  • Alkermes, Inc.$191
  • Teva Pharmaceuticals USA, Inc.$188
  • Otsuka America Pharmaceutical, Inc.$142
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$95
  • Takeda Pharmaceuticals U.S.A., Inc.$86
  • plus $126 from 5 others

What the payments were for

  • Food & beverage$1,24692%
  • Education$1118%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,358 in reported general payments places this provider in the 75th percentile of 328 psychiatry providers in Oklahoma.

See all psychiatry providers in Oklahoma

Medicare billing

Part B allowed, 2024
$32,645
Medicare patients
52
Services billed
454

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate12$83,848
VyvanseLisdexamfetamine Dimesylate12$4,713
Vilazodone Hcl23$2,433
Oxcarbazepine20$1,492
Olanzapine19$947
Aripiprazole14$929
Lurasidone Hcl12$916
Duloxetine Hcl18$785
Bupropion XlBupropion Hcl23$655
Amitriptyline Hcl26$432
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine13$307
Quetiapine Fumarate12$306
Clonazepam29$214
Lamotrigine21$183
Alprazolam XrAlprazolam14$173

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$86$4,71312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 328 psychiatry providers in Oklahoma.

Other psychiatry in Norman

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →